12.18  -0.18 (-1.46%)		11-26 16:00
Open: 12.54 High: 12.595 Volume: 93,623		Pre. Close: 12.36 Low: 12.095 Market Cap: 974(M)

Short term
Mid term
Targets	6-month :	14.75	1-year :	16.35
Resists	First :	12.63	Second :	14
Pivot price	12.61
Supports	First :	10.42	Second :	8.66
MAs	MA(5) :	12.27	MA(20) :	12.49
	MA(100) :	11.07	MA(250) :	10.87
MACD	MACD :	0.2	Signal :	0.3
%K %D	K(14,3) :	21.8	D(3) :	23
RSI	RSI(14): 49.1
52-week	High :	14	Low :	8.5

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BBOT ] has closed above bottom band by 26.6%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	12.62 - 12.69	12.69 - 12.74
Low:	11.93 - 12.01	12.01 - 12.08
Close:	12.06 - 12.19	12.19 - 12.29

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Tue, 25 Nov 2025
BBOT: Wedbush Reiterates Outperform Rating with $25 Target | BBO - GuruFocus

Tue, 18 Nov 2025
BridgeBio Oncology Therapeutics Reports Q3 2025 Progress - TipRanks

Tue, 18 Nov 2025
BBOT to Participate in Upcoming December Investor Healthcare Conferences - GlobeNewswire

Sat, 15 Nov 2025
Decoding BridgeBio Oncology Therapeutics Inc (BBOT): A Strategic SWOT Insight - GuruFocus

Thu, 13 Nov 2025
Oppenheimer Maintains BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - Nasdaq

Wed, 12 Nov 2025
BridgeBio Oncology Therapeutics, Inc.'s (NASDAQ:BBOT) largest shareholders are individual investors who were rewarded as market cap surged US$51m last week - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	80 (M)
Shares Float	0 (M)
Held by Insiders	24 (%)
Held by Institutions	52.8 (%)
Shares Short	816 (K)
Shares Short P.Month	1,110 (K)

EPS	-1.46
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-558.92
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	-81 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-8.4
PEG Ratio	0
Price to Book value	-0.03
Price to Sales	0
Price to Cash Flow	-12.05

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.